The Role of the Human Microbiome in Preventing Health Care-Associated Infections

The microbiome is influenced by various factors, including vertical transmission from the mother and dietary habits. Hospitalization can significantly impact a patient’s microbiome due to dietary changes, stress, and the use of antimicrobials, often decreasing its diversity and functionality. This disruption can impair the microbiome's ability to defend against pathogens, complicating patient recovery.

The microbiome also plays a vital role in immune system development. From birth, the microbial composition helps to develop immune cells and systems involved in metabolic and inflammatory responses. Historically, the microbiome's role in health has not been sufficiently recognized, despite its integral connection to disease processes. For instance, a healthy gut microbiome can enhance the efficacy of chemotherapy in cancer patients.

Development of HAIs requires a susceptible host, a pathogen, and transmission dynamics. While many pathogens originate externally, numerous HAIs also arise from a patient’s endogenous microbiota. Studies reveal that about 20% of patients colonized with multidrug-resistant organisms (MDROs) may develop infections from those same organisms during their ICU stay.

Dysbiosis, an imbalance favoring pathogenic microorganisms over beneficial ones, increases the risk for HAIs. Antimicrobial usage can disrupt the microbiota, promoting the growth of harmful pathogens and the transmission of resistance genes, which can then affect other individuals who have not received such treatments. Alarmingly, changes to the microbiota from antibiotics can persist for years.

Research has linked alterations in the microbiome to negative outcomes during ICU admissions, including the development of respiratory infections. Additionally, the health care environment itself—encompassing equipment, personnel, and cleaning practices—significantly affects patient microbiomes. Samples from health care workers have shown contamination with pathogens, and studies indicate that patient microbiota can alter the environmental microbiome during their hospitalization.

Interventions to modify the microbiome for therapeutic purposes, such as fecal microbiota transplantation (FMT), have been used effectively to treat recurrent C. difficile infections. While promising, FMT poses risks, including potential pathogen transmission from donor feces. Probiotics and phage technologies are being researched for their roles in enhancing microbiota and combating gut pathogens.

Traditional infection prevention methods are insufficient alone, necessitating integrated approaches that include antimicrobial stewardship. Proper testing and medication administration can help maintain microbiome health and reduce resistance. Advances in cleaning practices, such as using probiotic-infused disinfectants, offer innovative methods to combat pathogenic organisms in health care settings.

In conclusion, encouraging microbiome diversity could serve as a biomarker for identifying patients at higher risk for HAIs. As the understanding of the microbiome’s role in infection prevention deepens, the medical community can develop targeted strategies to bolster patient resilience and mitigate the risks associated with dysbiosis.